NADAC acquisition cost data for GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
| 72065012012 | $2,853.59 | 2022-02-01 | Rx |
Generic: Glucagon | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2022 | $215.3K | 545 | 471 | $1,562.74 |
| 2023 | $624.5K | 1,419 | 1,079 | $1,607.06 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Ohio | $75.1K | 119 | 81 |
| California | $58.5K | 123 | 99 |
| New York | $46.0K | 98 | 53 |
| Pennsylvania | $36.6K | 87 | 68 |
| New Jersey | $30.9K | 81 | 58 |
| Illinois | $28.4K | 75 | 63 |
| Massachusetts | $28.4K | 62 | 35 |
| Florida | $27.4K | 76 | 66 |
| Wisconsin | $27.0K | 55 | 47 |
| Georgia | $24.8K | 61 | 46 |
| Texas | $19.5K | 50 | 41 |
| Kentucky | $14.6K | 33 | 26 |
| Missouri | $13.2K | 28 | 25 |
| North Carolina | $12.8K | 35 | 32 |
| Tennessee | $12.5K | 28 | 27 |
| Maryland | $12.0K | 16 | 11 |
| South Carolina | $11.8K | 30 | 20 |
| Michigan | $11.4K | 24 | 20 |
| Colorado | $10.2K | 31 | N/A |
| Indiana | $9.9K | 25 | 22 |
| Kansas | $8.6K | 20 | 17 |
| Arizona | $8.2K | 24 | 20 |
| Mississippi | $7.0K | 19 | 15 |
| Louisiana | $6.9K | 20 | 16 |
| Connecticut | $6.5K | 15 | 14 |
| West Virginia | $6.0K | 16 | N/A |
| Maine | $5.8K | 15 | 15 |
| Virginia | $5.8K | 14 | 14 |
| Oklahoma | $5.5K | 12 | N/A |
| Alabama | $5.2K | 13 | 12 |
| Washington | $4.3K | 11 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.